SCHEMBL5643186

SCHEMBL5643186

O=C1Cn2c(nc(C(=O)NCc3ccc(F)cc3)c(O)c2=O)N1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.50
CYP2C9 P11712 1/20 0.50
ERCC1 P07992 1/20 0.47
FEN1 P39748 1/20 0.47
ERCC4 Q92889 1/20 0.47
KCNE1 P15382 1/20 0.47
CCR1 P32246 1/20 0.47
KCNQ1 P51787 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
CALCA P06881 1/20 0.43
GAA P10253 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
LIPG Q9Y5X9 2/20 0.42
ALDH1A1 P00352 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537432 0.89 KCNH2 (0.51) KCNH2CYP2C9ERCC1FEN1ERCC4
SCHEMBL5539177 0.86 MMP13 (0.47) KCNH2CYP2C9KCNE1CCR1KCNQ1
SCHEMBL5538310 0.86 KCNH2 (0.39) KCNH2CYP2C9
SCHEMBL13238867 0.85 KCNH2 (0.47) KCNH2CYP2C9ERCC1FEN1ERCC4
SCHEMBL5534183 0.84 NPC1 (0.40) KCNH2CYP2C9KCNE1CCR1KCNQ1
SCHEMBL5647057 0.84 CNR1 (0.42) MEN1KMT2AALDH1A1
SCHEMBL5537529 0.83 KCNH2 (0.49) KCNH2CYP2C9ERCC1FEN1ERCC4
SCHEMBL2207679 0.83 KCNH2 (0.49) KCNH2CYP2C9ERCC1FEN1ERCC4
SCHEMBL14567056 0.83 KCNH2 (0.52) KCNH2CYP2C9ERCC1FEN1ERCC4
SCHEMBL2205929 0.83 KCNH2 (0.49) KCNH2CYP2C9ERCC1FEN1ERCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050267132-A1 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-12-01 US claimed
US-7192948-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-20 US disclosed
US-7192948-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-20 US disclosed
US-7192948-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-20 US disclosed
US-20050267132-A1 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267132-A1 Bicyclic heterocycles as HIV integrase inhibitors CCNI, TOP1, APOBEC3C KCNH2 3080/4885CYP2C9 237/4885ERCC1 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.